Clinical efficacy of rubella vaccine. NLM AIDSLINE Important note: Information in this article was accurate in 1983. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Clinical efficacy of rubella vaccine.

Pediatr Infect Dis. 1983 Jul-Aug;2(4):284-6. Unique Identifier : AIDSLINE MED/83299583
Greaves WL; Orenstein WA; Hinman AR; Nersesian WS

Abstract: In the period October 10, 1980, to January 19, 1981, 83 cases of rash illness compatible with rubella were reported in Sanford, ME. Twenty-two (27%) were confirmed serologically. Forty cases (48%) occurred in Sanford High School students; the overall attack rate was 3.2%. A case-control study was undertaken to determine the effectiveness of rubella vaccine in preventing clinical rubella. Bayes' theorem was used to calculate the attack rates in the vaccinated population (ARV) and the unvaccinated population (ARU). Vaccine efficacy (VE), calculated with use of the formula VE (%) = [(ARU - ARV)/ARU] x 100, was 90%. These results indicate that rubella vaccine is highly effective in preventing clinical rubella and do not support proposals for routine revaccination.
Keywords: Adolescence Adult Bayes Theorem Child Child, Preschool Disease Outbreaks/EPIDEMIOLOGY/*PREVENTION & CONTROL Female Human Infant Maine Male Middle Age Rubella/EPIDEMIOLOGY/*PREVENTION & CONTROL Rubella Vaccine/*ADMINISTRATION & DOSAGE Vaccination JOURNAL ARTICLE

KWDadolescenceadultbayestheoremchildchild,preschooldiseaseoutbreaks/epidemiology/KWDprevention&controlfemalehumaninfantmainemalemiddleagerubella/epidemiology/KWDprevention&controlrubellavaccine/KWDadministration&dosagevaccinationjournalarticle
831230
M83C0058

Copyright © 1983 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1983. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1983. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .